PerkinElmer Stock Continues to Climb

Shares in PerkinElmer rose 5.54 percent for the five-day trading period ended Tuesday, continuing a steady ascent over recent weeks. The firm's shares closed at $21.15 on Tuesday, a price not reached since March 29, when PKI's shares rose as high as $21.97. Its low for the last three months was $18, which occurred on June 27. The volume of trading in the firm's shares was also relatively heavy early this week, though no news was announced.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.